1
NURS 6630 Psychopharmacology Midterm Exam
2026/2027 Actual Exam | Summer Qtr with Questions
& Correct Answers with Detailed Rationales | Walden
University | Pass Guaranteed - A+ Graded
Section 1: Neurobiology and Receptor Pharmacology
Q1: A patient is started on fluoxetine (Prozac) for major depressive disorder. The PMHNP
understands that the therapeutic effect of SSRIs is primarily due to:
A. Blocking dopamine D2 receptors
B. Inhibiting the reuptake of serotonin at the presynaptic neuron [CORRECT]
C. Blocking acetylcholinesterase
D. Enhancing GABA activity
Correct Answer: B
Rationale: SSRIs work by selectively inhibiting the reuptake of serotonin at the presynaptic
neuron, increasing serotonin availability in the synaptic cleft. Option A describes antipsychotics.
Option C describes Alzheimer's medications. Option D describes benzodiazepines and other
GABAergic drugs.
Q2: The PMHNP is explaining the concept of "downregulation" to a student. This phenomenon
refers to:
A. An increase in the number of receptors due to chronic antagonist use
B. A decrease in the number of receptors due to chronic agonist use [CORRECT]
C. An increase in receptor sensitivity due to lack of neurotransmitter
D. The movement of receptors into the cytoplasm for storage
Correct Answer: B
Rationale: Downregulation is a homeostatic mechanism where chronic exposure to an agonist
leads to a decrease in the number of receptors, often contributing to tolerance. Upregulation
(Option A) occurs with antagonist use.
,2
Q3: Which of the following neurotransmitters is primarily associated with the positive symptoms
of schizophrenia (hallucinations, delusions) due to hyperactivity in the mesolimbic pathway?
A. Norepinephrine
B. Serotonin
C. Dopamine [CORRECT]
D. Glutamate
Correct Answer: C
Rationale: The dopamine hypothesis of schizophrenia posits that hyperactivity of dopamine
transmission in the mesolimbic pathway causes positive symptoms. Antipsychotics work
primarily by blocking D2 receptors in this pathway.
Q4: A patient presents with EPS (extrapyramidal symptoms) after starting an antipsychotic. The
PMHNP recognizes this is due to dopamine antagonism in which pathway?
A. Mesocortical pathway
B. Mesolimbic pathway
C. Nigrostriatal pathway [CORRECT]
D. Tuberoinfundibular pathway
Correct Answer: C
Rationale: The nigrostriatal pathway regulates motor control. Blockade of D2 receptors here
causes EPS (dystonia, akathisia, parkinsonism). Blockade in the tuberoinfundibular pathway
causes hyperprolactinemia.
Q5: When prescribing a medication that acts as an "inverse agonist," the PMHNP understands
that the medication:
A. Binds to the receptor without activating it, blocking the agonist
B. Binds to the receptor and produces an effect opposite to that of an agonist [CORRECT]
, 3
C. Increases the efficacy of the endogenous neurotransmitter
D. Only works on ion-gated channels
Correct Answer: B
Rationale: An inverse agonist binds to the same receptor as an agonist but induces a
pharmacological response opposite to that of the agonist. A neutral antagonist (Option A) merely
blocks the agonist.
Q6: G-protein coupled receptors (GPCRs) are the target of many psychiatric drugs. Which of the
following is characteristic of GPCRs?
A. They are fast-acting ion channels
B. They utilize a second messenger system for signal transduction [CORRECT]
C. They do not require ligand binding to activate
D. They are the only receptor type for dopamine
Correct Answer: B
Rationale: GPCRs are metabotropic receptors that use second messenger systems (like cAMP or
phospholipase C) to create slow, prolonged effects. Ion channels (Option A) are ligand-gated ion
channels (ionotropic).
Q7: A patient is taking a medication that inhibits the CYP2D6 enzyme. The PMHNP should be
aware that this may:
A. Decrease the metabolism of substrates of CYP2D6, increasing their plasma levels
[CORRECT]
B. Increase the metabolism of substrates of CYP2D6, decreasing their plasma levels
C. Have no effect on drug metabolism
D. Induce the production of CYP3A4
Correct Answer: A
NURS 6630 Psychopharmacology Midterm Exam
2026/2027 Actual Exam | Summer Qtr with Questions
& Correct Answers with Detailed Rationales | Walden
University | Pass Guaranteed - A+ Graded
Section 1: Neurobiology and Receptor Pharmacology
Q1: A patient is started on fluoxetine (Prozac) for major depressive disorder. The PMHNP
understands that the therapeutic effect of SSRIs is primarily due to:
A. Blocking dopamine D2 receptors
B. Inhibiting the reuptake of serotonin at the presynaptic neuron [CORRECT]
C. Blocking acetylcholinesterase
D. Enhancing GABA activity
Correct Answer: B
Rationale: SSRIs work by selectively inhibiting the reuptake of serotonin at the presynaptic
neuron, increasing serotonin availability in the synaptic cleft. Option A describes antipsychotics.
Option C describes Alzheimer's medications. Option D describes benzodiazepines and other
GABAergic drugs.
Q2: The PMHNP is explaining the concept of "downregulation" to a student. This phenomenon
refers to:
A. An increase in the number of receptors due to chronic antagonist use
B. A decrease in the number of receptors due to chronic agonist use [CORRECT]
C. An increase in receptor sensitivity due to lack of neurotransmitter
D. The movement of receptors into the cytoplasm for storage
Correct Answer: B
Rationale: Downregulation is a homeostatic mechanism where chronic exposure to an agonist
leads to a decrease in the number of receptors, often contributing to tolerance. Upregulation
(Option A) occurs with antagonist use.
,2
Q3: Which of the following neurotransmitters is primarily associated with the positive symptoms
of schizophrenia (hallucinations, delusions) due to hyperactivity in the mesolimbic pathway?
A. Norepinephrine
B. Serotonin
C. Dopamine [CORRECT]
D. Glutamate
Correct Answer: C
Rationale: The dopamine hypothesis of schizophrenia posits that hyperactivity of dopamine
transmission in the mesolimbic pathway causes positive symptoms. Antipsychotics work
primarily by blocking D2 receptors in this pathway.
Q4: A patient presents with EPS (extrapyramidal symptoms) after starting an antipsychotic. The
PMHNP recognizes this is due to dopamine antagonism in which pathway?
A. Mesocortical pathway
B. Mesolimbic pathway
C. Nigrostriatal pathway [CORRECT]
D. Tuberoinfundibular pathway
Correct Answer: C
Rationale: The nigrostriatal pathway regulates motor control. Blockade of D2 receptors here
causes EPS (dystonia, akathisia, parkinsonism). Blockade in the tuberoinfundibular pathway
causes hyperprolactinemia.
Q5: When prescribing a medication that acts as an "inverse agonist," the PMHNP understands
that the medication:
A. Binds to the receptor without activating it, blocking the agonist
B. Binds to the receptor and produces an effect opposite to that of an agonist [CORRECT]
, 3
C. Increases the efficacy of the endogenous neurotransmitter
D. Only works on ion-gated channels
Correct Answer: B
Rationale: An inverse agonist binds to the same receptor as an agonist but induces a
pharmacological response opposite to that of the agonist. A neutral antagonist (Option A) merely
blocks the agonist.
Q6: G-protein coupled receptors (GPCRs) are the target of many psychiatric drugs. Which of the
following is characteristic of GPCRs?
A. They are fast-acting ion channels
B. They utilize a second messenger system for signal transduction [CORRECT]
C. They do not require ligand binding to activate
D. They are the only receptor type for dopamine
Correct Answer: B
Rationale: GPCRs are metabotropic receptors that use second messenger systems (like cAMP or
phospholipase C) to create slow, prolonged effects. Ion channels (Option A) are ligand-gated ion
channels (ionotropic).
Q7: A patient is taking a medication that inhibits the CYP2D6 enzyme. The PMHNP should be
aware that this may:
A. Decrease the metabolism of substrates of CYP2D6, increasing their plasma levels
[CORRECT]
B. Increase the metabolism of substrates of CYP2D6, decreasing their plasma levels
C. Have no effect on drug metabolism
D. Induce the production of CYP3A4
Correct Answer: A
